Title
Category
Credits
Event date
Cost
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
During this activity, presenters will discuss CF and the different genetic etiologies and examine how an individual’s genetic profile can be utilized to develop a personalized treatment plan. The role that an informed interprofessional health care team can play in improved disease outcomes will also be examined. 
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will discuss the effects and complications of SCD, the prevalence of SCD in different racial and ethnic groups and the role of gene therapy as treatment. Health disparities and challenges in accessing specialized care will also be addressed.
  • Disease management
  • Oncology
  • Transplantation
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will provide an overview of the living-donor liver transplant procedure, the advantages and disadvantages of living-donor liver transplant, and the optimal timing for offering living donations to patients with liver cancer. Dr. Hughes will discuss the innovative approach advanced by experts at UPMC in which patients with liver cancer are offered the option of a living-donor transplant. He will discuss the experience and expertise offered by the UPMC Liver Transplant Program and their collaborative approach to working with referring physicians.
  • Disease management
  • Health equity
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will focus on the connection between SDoH and how they may impact access to care, treatment and health outcomes for children with rare and CMC. Learners will be provided with strategies and resources that can address these negative effects. The importance of access to personalized care that they require to live their healthiest lives will be addressed.
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will discuss emerging therapies for DMD and the importance of incorporating a personalized interprofessional care plan, along with the role of health disparities and how these impacts access to care and outcomes for these individuals.
  • Disease management
  • Older adults
  • Oncology
  • Transplantation
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will provide an overview of geriatric and frailty assessment tools that can assist in guiding cancer- and transplant-related decision making through the risk stratification of older individuals before therapy is initiated. Data surrounding the relationship among increased age, geriatric- and frailty-assessment results, and disease outcomes will also be explored. Key considerations in how to best incorporate these sometimes time-intensive assessments into practice will be outlined, along with discussion of how interprofessional collaboration among members of the health care team in the creation of care plans can facilitate quality care.
  • Disease management
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
$0.00
This activity will review the symptoms and signs of SM, provide an overview of new and current therapies and identify SM guideline updates. The value of an interdisciplinary team–based approach along the continuum of care for affected individuals will also be discussed as a definitive step toward optimizing outcomes. 
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This session examines the cost of development and growth of these pharmaceuticals and details the specific role that specialty pharmacy plays in making these products accessible. The high costs of therapies and patient and medication management are also discussed along with the role and value of drug benefit programs.
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity examines current data about chronic kidney disease (CKD), including its health outcomes and relationships with cardiovascular and metabolic disease. Treatment regimens aimed at delaying progression and their outcomes are reviewed, along with current knowledge regarding the pathophysiologic and genetic basis of this disease. Areas of emerging interest in research on potential new treatments targeting the causes of CKD are discussed, including genomic analysis, and their relevance to clinical care.
  • Disease management
  • Transplantation
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This session focuses on developing equal access to transplant services for the Hispanic population, as well as on how equity-based approaches can be used as a model for treatment programs for other diseases, such as sickle cell disease, immunodeficiencies, cancer, and other chronic conditions.

Pages